365 related articles for article (PubMed ID: 27614448)
1. Could CRISPR be the solution for gene editing's Gordian knot?
Fang H; Wang W
Cell Biol Toxicol; 2016 Dec; 32(6):465-467. PubMed ID: 27614448
[No Abstract] [Full Text] [Related]
2. The Implications of CRISPR-Cas9 Genome Editing for IR.
Perkons NR; Sheth R; Ackerman D; Chen J; Saleh K; Hunt SJ; Nadolski GJ; Shi J; Gade TP
J Vasc Interv Radiol; 2018 Sep; 29(9):1264-1267.e1. PubMed ID: 30146193
[No Abstract] [Full Text] [Related]
3. Ji Luo Elucidates the CRISPR Gene Editing Technology, and How It May Affect Cancer Therapy in the Future.
Luo J
Oncology (Williston Park); 2016 Oct; 30(10):879. PubMed ID: 27753053
[No Abstract] [Full Text] [Related]
4. A Toolkit of CRISPR-Based Genome Editing Systems in Drosophila.
Xu J; Ren X; Sun J; Wang X; Qiao HH; Xu BW; Liu LP; Ni JQ
J Genet Genomics; 2015 Apr; 42(4):141-9. PubMed ID: 25953352
[TBL] [Abstract][Full Text] [Related]
5. Energy biotechnology in the CRISPR-Cas9 era.
Estrela R; Cate JH
Curr Opin Biotechnol; 2016 Apr; 38():79-84. PubMed ID: 26874259
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.
Chadwick AC; Musunuru K
Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):12-18. PubMed ID: 28838920
[TBL] [Abstract][Full Text] [Related]
7. Use of CRISPR/Cas Genome Editing Technology for Targeted Mutagenesis in Rice.
Xu R; Wei P; Yang J
Methods Mol Biol; 2017; 1498():33-40. PubMed ID: 27709567
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report.
Wang X; Raghavan A; Chen T; Qiao L; Zhang Y; Ding Q; Musunuru K
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):783-6. PubMed ID: 26941020
[TBL] [Abstract][Full Text] [Related]
9. Genome editing: The efficient tool CRISPR-Cpf1.
Mahfouz MM
Nat Plants; 2017 Mar; 3():17028. PubMed ID: 28260792
[No Abstract] [Full Text] [Related]
10. The CRISPR-Cas toolbox and gene editing technologies.
Liu G; Lin Q; Jin S; Gao C
Mol Cell; 2022 Jan; 82(2):333-347. PubMed ID: 34968414
[TBL] [Abstract][Full Text] [Related]
11. Genome editing: The domestication of Cas9.
Urnov F
Nature; 2016 Jan; 529(7587):468-9. PubMed ID: 26819037
[No Abstract] [Full Text] [Related]
12. Brain tumor modeling using the CRISPR/Cas9 system: state of the art and view to the future.
Mao XY; Dai JX; Zhou HH; Liu ZQ; Jin WL
Oncotarget; 2016 May; 7(22):33461-71. PubMed ID: 26993776
[TBL] [Abstract][Full Text] [Related]
13. Special Issue on the Chemical Biology of CRISPR.
Weidmann AG; Choudhary A
ACS Chem Biol; 2018 Feb; 13(2):283-284. PubMed ID: 29448763
[No Abstract] [Full Text] [Related]
14. RNA-Targeting CRISPR-Cas Systems and Their Applications.
Burmistrz M; Krakowski K; Krawczyk-Balska A
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046217
[TBL] [Abstract][Full Text] [Related]
15. Repurposing type I-F CRISPR-Cas system as a transcriptional activation tool in human cells.
Chen Y; Liu J; Zhi S; Zheng Q; Ma W; Huang J; Liu Y; Liu D; Liang P; Songyang Z
Nat Commun; 2020 Jun; 11(1):3136. PubMed ID: 32561716
[TBL] [Abstract][Full Text] [Related]
16. Genome Editing in Retinal Diseases using CRISPR Technology.
Yiu G
Ophthalmol Retina; 2018 Jan; 2(1):1-3. PubMed ID: 31047294
[No Abstract] [Full Text] [Related]
17. More specific CRISPR editing.
de Souza N
Nat Methods; 2014 Jul; 11(7):712. PubMed ID: 25110782
[No Abstract] [Full Text] [Related]
18. A CRISPR Path to Cutting-Edge Materials.
Chen M; Luo D
N Engl J Med; 2020 Jan; 382(1):85-88. PubMed ID: 31893521
[No Abstract] [Full Text] [Related]
19. Now on Course, CRISPR J.
Newsham W
CRISPR J; 2019 Jun; 2():155-156. PubMed ID: 31225748
[No Abstract] [Full Text] [Related]
20. Cas9, Cpf1 and C2c1/2/3-What's next?
Nakade S; Yamamoto T; Sakuma T
Bioengineered; 2017 May; 8(3):265-273. PubMed ID: 28140746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
